2BB score and signals
Fate Therapeutics, Inc.’s current 2BB score is 36 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 55 | Moderate |
| Momentum | 44 | Stable |
| Financial strength | 9 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 51 | Moderate |
Company facts
| CEO | Scott Wolchko |
| Founded | 2007 |
| Employees | 161 |
| 52-week range | $0.93 – $3.23 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | -0.2847 | — | $1.26M |
| 2026-11-11 | — | -0.2704 | — | $1.28M |
| 2026-08-13 | — | -0.2732 | — | $1.39M |
| 2026-05-13 | -0.26 | -0.2856 | $1.30M | $1.16M |
Related companies
2BBBullish & Bearish